A Distinct Delayed-Onset Intraocular Inflammation Phenotype of Faricimab versus Aflibercept and Ranibizumab: Triangulated Pharmacovigilance Evidence from Databases of US, Europe and Japan
Purpose: Post-marketing reports have associated faricimab, the first intravitreal bispecific antibody, with intraocular inflammation (IOI). Its inflammator